Skip to main content

Table 2 Demographic and clinical data of subjects with diabetes by the presence and severity of PAD

From: Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes

Variables

All subjects

(n = 306)

No PAD

(n = 150)

Fontaine classification

P value for trend

II (n = 76)

III (n = 50)

IV (n = 30)

Male

52.9

45.3

47.4

44.0

53.3

0.606

Age (years)

61.2 ± 11.4

60.4 ± 12.0

59.2 ± 11.0

61.2 ± 11.0

62.6 ± 10.8

0.233

BMI (kg/m2)

25.2 ± 3.3

25.1 ± 3.4

25.1 ± 3.4

25.0 ± 3.5

24.8 ± 3.3

0.640

Current smoker

26.1

25.3

28.9

24.0

26.7

0.953

Hypertension

51.0

48.0

52.6

56.0

53.3

0.344

Diabetes duration (years)

8.6 ± 5.6

7.3 ± 6.1

9.6 ± 6.4

10.7 ± 6.0

12.8 ± 5.8

 < 0.001

Total cholesterol (mmol/L)

4.5 ± 1.3

4.6 ± 1.3

4.5 ± 1.3

4.7 ± 1.3

4.9 ± 1.1

0.172

TG (mmol/L)

1.8 ± 1.5

1.9 ± 1.7

1.8 ± 1.5

1.7 ± 1.4

1.8 ± 1.7

0.692

HDL-C (mmol/L)

1.2 ± 0.4

1.1 ± 0.4

1.2 ± 0.4

1.2 ± 0.4

1.3 ± 0.3

0.015

LDL-C (mmol/L)

3.1 ± 0.7

3.1 ± 0.9

3.1 ± 0.7

3.1 ± 0.7

3.2 ± 0.8

0.557

HbA1c (%)

8.8 ± 1.7

8.2 ± 1.5

8.9 ± 1.6

8.9 ± 1.5

9.1 ± 1.7

0.006

Fasting glucose (mmol/L)

7.4 ± 1.6

7.1 ± 1.5

7.9 ± 1.7

7.7 ± 1.5

8.1 ± 1.5

0.004

eGFR (ml/min/1.73 m2)

79.4 ± 8.4

82.3 ± 8.7

79.5 ± 8.9

78.5 ± 8.8

76.5 ± 8.4

 < 0.001

Serum Cyr61 (pg/ml)

219.1 ± 13.5

195.4 ± 11.9

221.0 ± 14.4

247.6 ± 11.8

275.5 ± 12.3

 < 0.001

Use antidiabetes agents

 Oral drugs

58.2

61.3

60.5

48.0

55.3

0.225

 Insulin

64.7

54.7

68.4

76.0

86.7

 < 0.001

Use antihypertension agents

 β-Blockers

13.1

10.7

13.2

16.0

20.0

0.123

 Calcium-channel blockers

24.2

24.0

23.7

24.0

26.7

0.826

 RAAS inhibitors

47.1

40.0

47.4

56.0

66.7

0.003

 Diuretics

6.5

5.3

7.9

8.0

6.7

0.551

Use lipid-lowering agents

 Statins

24.8

3221.3

2026.3

1428.0

1033.3

0.119

 Fibrates

7.2

85.3

810.5

48.0

26.7

0.530

  1. Data are the mean ± SD or percentage unless otherwise indicated
  2. BMI body mass index, RAAS renin–angiotensin–aldosterone system